CI
Neutral signalScored 2026-10-06 Drivers: Congress, fundamentals. Insiders: neutral. Moteurs : Congrès, fondamentaux. Initiés : neutre.
Research, not advice.
À propos
Cigna Corporation
- Nom
- Cigna Corporation
- Secteur
- Healthcare
- Industrie
- Medical - Healthcare Plans
- Bourse
- NYSE
- Capitalisation
- $81.1B
- Employés
- 66,685
- PDG
- Brian C. Evanko
- Site web
- https://www.thecignagroup.com
- Marché
- ALHCCNCCVSELVHUMMOH
Cigna Group, established in 1792 and headquartered in Bloomfield, Connecticut, provides insurance products and related services across the United States. The company operates through two primary segments. Its Evernorth division offers a comprehensive array of coordinated and specialized health solutions, including pharmacy services, benefits administration, care management and delivery, and advanced intelligence solutions. These offerings cater to a diverse clientele, such as health plans, employers, government entities, and healthcare providers. Meanwhile, the Cigna Healthcare segment delivers an extensive portfolio of products and services, encompassing medical, pharmaceutical, behavioral health, dental, vision, and health advocacy programs for both insured and self-insured customers. This segment also provides Medicare Advantage, Medicare Supplement, and Medicare Part D plans specifically for seniors, in addition to individual health insurance options available on and off public exchanges. Globally, Cigna Healthcare extends international health coverage and benefits to mobile professionals and employees of multinational organizations. Furthermore, the company issues permanent insurance contracts to corporations, designed to cover the lives of specific employees for funding future benefit obligations. Cigna distributes its various offerings through insurance brokers and consultants, direct sales channels to employers, unions, and individuals, and via both private and public exchanges.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 617 titres (~175259 USD)
- Insiders
- Neville Everett
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$6,293,359
Avg sell (VWAP, 90d window) $276.87 vs last close —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
$6,293,359 of that total is under a Rule 10b5-1 plan. It is shown here and left out of the score.
- Last activity
- 2026-09-03
- Last synced
-
2026-10-06 10:56:08
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-09-03 | Neville Everett | Sell · S · 10b5-1 | 617 | $284.05 | $175,259 | Form 4 |
| 2026-08-18 | Jones Nicole S | Sell · S · 10b5-1 | 2,677 | $279.61 | $748,516 | Form 4 |
| 2026-08-04 | Jones Nicole S | Sell · S · 10b5-1 | 19,436 | $276.27 | $5,369,584 | Form 4 |
Sales marked 10b5-1 are scheduled in advance and don't count toward the Quorum score. Les ventes marquées 10b5-1 sont planifiées à l'avance et ne pèsent pas dans le score Quorum.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
| Date | Member | Side | Amount range | Filing |
|---|---|---|---|---|
| 2026-09-11 | Ro Khanna | Buy | $1,001 - $15,000 | Filing |
| 2026-09-04 | Ro Khanna | Buy | $1,001 - $15,000 | Filing |
| 2025-09-23 | Julie Johnson | Buy | $1,001 - $15,000 | Filing |
| 2025-09-23 | Julie Johnson | Buy | $1,001 - $15,000 | Filing |
| 2025-09-22 | Julie Johnson | Buy | $1,001 - $15,000 | Filing |
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2026-03-23 | Jared Moskowitz | Sale (Full) | $1,001 - $15,000 |
| 2026-03-23 | Jared Moskowitz | Sale (Full) | $1,001 - $15,000 |
| 2026-03-13 | Gilbert Ray Cisneros | Sale (Full) | $1,001 - $15,000 |
| 2026-01-13 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2025-12-19 | Gilbert Ray Cisneros | Purchase | $1,001 - $15,000 |
| 2025-12-18 | Julie Johnson | Sale (Full) | $1,001 - $15,000 |
| 2025-11-13 | Julie Johnson | Sale (Partial) | $1,001 - $15,000 |
| 2025-11-12 | Gilbert Ray Cisneros | Sale (Full) | $1,001 - $15,000 |
| 2025-10-30 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2025-10-30 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2025-09-29 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2025-09-25 | Julie Johnson | Sale (Full) | $1,001 - $15,000 |
| 2025-09-23 | Julie Johnson | Purchase | $1,001 - $15,000 |
| 2025-09-23 | Julie Johnson | Sale (Full) | $1,001 - $15,000 |
| 2025-09-23 | Val Hoyle | Sale (Full) | $1,001 - $15,000 |
| 2025-09-05 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2025-08-14 | Julie Johnson | Sale (Partial) | $1,001 - $15,000 |
| 2025-08-05 | Gilbert Ray Cisneros | Sale (Partial) | $1,001 - $15,000 |
| 2025-05-15 | Jared Moskowitz | Purchase | $1,001 - $15,000 |
| 2025-05-15 | Jared Moskowitz | Purchase | $1,001 - $15,000 |
| 2025-05-12 | Jefferson Shreve | Sale (Full) | $15,001 - $50,000 |
| 2025-04-22 | Julia Letlow | Sale (Full) | $1,001 - $15,000 |
| 2025-03-19 | Julie Johnson | Purchase | $1,001 - $15,000 |
| 2025-03-03 | Julie Johnson | Sale | $1,001 - $15,000 |
| 2025-02-25 | Robert P. Bresnahan | Sale (Full) | $1,001 - $15,000 |
| 2025-02-24 | Jefferson Shreve | Purchase | $15,001 - $50,000 |
| 2025-01-24 | Gilbert Ray Cisneros | Sale (Partial) | $1,001 - $15,000 |
| 2025-01-15 | Julie Johnson | Purchase | $1,001 - $15,000 |
| 2025-01-13 | Robert P. Bresnahan | Sale (Full) | $1,001 - $15,000 |
| 2024-10-29 | Val Hoyle | Purchase | $1,001 - $15,000 |
| 2024-10-23 | Julia Letlow | Purchase | $1,001 - $15,000 |
| 2024-10-14 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2024-09-09 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2024-01-16 | Ro Khanna | Purchase | $15,001 - $50,000 |
| 2023-10-02 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-09-08 | Lois Frankel | Sale (Full) | $15,001 - $50,000 |
| 2023-07-21 | Michael C. Burgess | Sale (Full) | $15,001 - $50,000 |
| 2023-06-29 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-05-31 | Lois Frankel | Purchase | $1,001 - $15,000 |
| 2023-05-23 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-05-19 | Ro Khanna | Purchase | $15,001 - $50,000 |
| 2023-04-17 | Ro Khanna | Sale | $15,001 - $50,000 |
| 2023-04-05 | Lois Frankel | Purchase | $1,001 - $15,000 |
| 2023-03-24 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-02-24 | Michael C. Burgess | Purchase | $15,001 - $50,000 |
| 2023-02-10 | Ro Khanna | Purchase | $15,001 - $50,000 |
| 2023-01-09 | Ro Khanna | Purchase | $15,001 - $50,000 |
| 2022-12-06 | Ro Khanna | Sale | $50,001 - $100,000 |
| 2022-11-02 | Lois Frankel | Sale (Partial) | $1,001 - $15,000 |
| 2022-09-29 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-05-18 | Lois Frankel | Sale (Partial) | $1,001 - $15,000 |
| 2022-05-10 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-04-21 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-02-14 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-01-20 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-01-11 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2021-11-19 | Michael C. Burgess | Sale (Partial) | $15,001 - $50,000 |
| 2021-10-05 | Thomas Suozzi | Sale (Partial) | $1,001 - $15,000 |
| 2021-10-05 | Thomas Suozzi | Sale (Full) | $1,001 - $15,000 |
| 2021-06-09 | Lois Frankel | Purchase | $1,001 - $15,000 |
| 2021-06-04 | Thomas Suozzi | Sale (Partial) | $15,001 - $50,000 |
| 2021-06-04 | Thomas Suozzi | Sale (Full) | $15,001 - $50,000 |
| 2021-02-16 | Peter Meijer | Sale (Full) | $1,001 - $15,000 |
| 2021-01-21 | Lois Frankel | Sale (Partial) | $1,001 - $15,000 |
| 2020-03-18 | Gilbert Ray Cisneros | Sale (Partial) | $1,001 - $15,000 |
| 2020-01-09 | Thomas Suozzi | Purchase | $15,001 - $50,000 |
| 2019-12-18 | Gerald E. Connolly | Sale (Full) | $1,001 - $15,000 |
| 2019-11-18 | Thomas Suozzi | Sale (Partial) | $50,001 - $100,000 |
| 2019-11-18 | Thomas Suozzi | Sale (Full) | $50,001 - $100,000 |
| 2019-10-17 | Thomas Suozzi | Sale (Partial) | $1,001 - $15,000 |
| 2019-10-02 | Lois Frankel | Purchase | $1,001 - $15,000 |
| 2019-09-16 | Thomas Suozzi | Sale (Partial) | $1,001 - $15,000 |
| 2019-08-14 | Gilbert Ray Cisneros | Purchase | $1,001 - $15,000 |
| 2019-08-14 | Lois Frankel | Purchase | $1,001 - $15,000 |
| 2019-05-08 | Thomas Suozzi | Purchase | $15,001 - $50,000 |
| 2019-04-12 | Thomas Suozzi | Purchase | $50,001 - $100,000 |
| 2019-03-06 | Dean Phillips | Sale (Partial) | $1,001 - $15,000 |
| 2019-03-05 | Alan Lowenthal | Sale (Partial) | $50,001 - $100,000 |
| 2019-03-05 | Alan Lowenthal | Sale (Full) | $1,001 - $15,000 |
| 2019-03-05 | Alan Lowenthal | Sale (Partial) | $1,001 - $15,000 |
| 2019-03-05 | Alan Lowenthal | Sale (Full) | $50,001 - $100,000 |
| 2019-02-13 | Lois Frankel | Purchase | $1,001 - $15,000 |
| 2019-02-06 | Gilbert Ray Cisneros | Purchase | $1,001 - $15,000 |
| 2019-02-04 | Alan Lowenthal | Purchase | $50,001 - $100,000 |
| 2019-02-04 | Alan Lowenthal | Purchase | $1,001 - $15,000 |
| 2019-01-23 | Lois Frankel | Purchase | $1,001 - $15,000 |
| 2019-01-04 | Dean Phillips | Sale (Partial) | $1,001 - $15,000 |
| 2018-12-24 | Gerald E. Connolly | Exchange | $1,001 - $15,000 |
| 2018-12-14 | Alan Lowenthal | Purchase | $1,001 - $15,000 |
| 2018-10-31 | Lois Frankel | Sale (Partial) | $1,001 - $15,000 |
| 2018-08-06 | Gary James Palmer | Purchase | $1,001 - $15,000 |
| 2018-07-31 | Gary James Palmer | Sale (Full) | $1,001 - $15,000 |
| 2018-07-25 | Thomas Suozzi | Sale (Full) | $1,001 - $15,000 |
| 2018-04-17 | Thomas Suozzi | Purchase | $1,001 - $15,000 |
| 2018-02-07 | Rick W. Allen | Sale (Full) | $15,001 - $50,000 |
Signal
Neutral signalScored 2026-10-06 Drivers: Congress, fundamentals. Insiders: neutral. Moteurs : Congrès, fondamentaux. Initiés : neutre.
CI presents a weak composite profile with constrained financial health (liquidity score 40, current ratio below 1.0) and a modest earnings catalyst (score 35) undermined by insider selling and negative post-event price…
The first sentence of the analysis written for CI on 2026-10-06 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Neutral signal
Drivers: Congress, fundamentals. Insiders: neutral. Moteurs : Congrès, fondamentaux. Initiés : neutre.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Unavailable or mixed. – Insider: neutral. All sales (≈ $6.3M) were pre-planned Rule 10b5-1 trades, excluded from the score. No open-market buys or discretionary sales. – Initiés : neutre. Toutes les ventes (≈ $6.3M) sont sous plan 10b5-1 préétabli, exclues du score. Aucun achat ni vente discrétionnaire.
- Congress Unavailable or mixed. 1 purchase disclosure year to date, a thin reading
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Timing Unavailable or mixed. No stored price series
- Financial indicators Pulls against a bullish reading. Current ratio 0.85 · operating margin 3.3%
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 9.5% | 10.5% | 12.9% | 13.0% | 13.2% | |
| Ebit Margin | 3.3% | 3.9% | 4.6% | 4.8% | 4.7% | |
| Ebitda Margin | 4.2% | 4.6% | 5.6% | 5.8% | 5.7% | |
| Operating Profit Margin | 3.3% | 3.8% | 4.4% | 4.7% | 4.6% | |
| Pretax Profit Margin | 2.8% | 2.1% | 2.8% | 4.7% | 3.9% | |
| Continuous Operations Profit Margin | 2.3% | 1.5% | 2.8% | 3.8% | 3.1% | |
| Net Profit Margin | 2.2% | 1.4% | 2.6% | 3.7% | 3.1% | |
| Bottom Line Profit Margin | 2.2% | 1.4% | 2.6% | 3.7% | 3.1% | |
| Current Ratio | 0.849 | 0.843 | 0.767 | 0.731 | 0.829 | |
| Quick Ratio | 0.718 | 0.727 | 0.651 | 0.615 | 0.744 | |
| Solvency Ratio | 0.074 | 0.045 | 0.066 | 0.086 | 0.067 | |
| Cash Ratio | 0.136 | 0.130 | 0.161 | 0.144 | 0.117 | |
| Price To Earnings Ratio | 12.342 | 22.542 | 17.043 | 15.297 | 14.451 | |
| Price To Earnings Growth Ratio | 0.150 | -0.744 | -0.903 | 0.421 | -0.460 | |
| Forward Price To Earnings Growth Ratio | 0.150 | -0.744 | -0.903 | 0.421 | -0.460 | |
| Price To Earnings Diluted Ratio | 12.415 | 22.784 | 17.220 | 15.476 | 14.580 | |
| Price To Earnings Diluted Growth Ratio | 0.150 | -0.752 | -0.917 | 0.431 | -0.464 | |
| Price To Book Ratio | 1.755 | 1.886 | 1.923 | 2.312 | 1.647 | |
| Price To Sales Ratio | 0.266 | 0.313 | 0.455 | 0.575 | 0.446 | |
| Price To Free Cash Flow Ratio | 8.725 | 8.641 | 8.682 | 14.092 | 12.855 | |
| Price To Operating Cash Flow Ratio | 7.624 | 7.469 | 7.526 | 11.984 | 10.792 | |
| Debt To Assets Ratio | 0.199 | 0.205 | 0.202 | 0.219 | 0.221 | |
| Debt To Equity Ratio | 0.754 | 0.779 | 0.669 | 0.703 | 0.727 | |
| Debt To Capital Ratio | 0.430 | 0.438 | 0.401 | 0.413 | 0.421 | |
| Long Term Debt To Capital Ratio | 0.425 | 0.413 | 0.378 | 0.385 | 0.398 | |
| Financial Leverage Ratio | 3.786 | 3.799 | 3.305 | 3.207 | 3.288 | |
| Working Capital Turnover Ratio | -31.179 | -24.140 | -17.382 | -19.472 | -22.230 | |
| Operating Cash Flow Ratio | 0.170 | 0.179 | 0.242 | 0.210 | 0.165 | |
| Operating Cash Flow Sales Ratio | 0.035 | 0.042 | 0.060 | 0.048 | 0.041 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.874 | 0.864 | 0.867 | 0.850 | 0.840 | |
| Debt Service Coverage Ratio | 5.201 | 2.249 | 2.562 | 2.106 | 2.304 | |
| Interest Coverage Ratio | 6.610 | 6.562 | 5.903 | 6.881 | 6.574 | |
| Short Term Operating Cash Flow Coverage Ratio | 16.218 | 3.464 | 4.322 | 2.924 | 2.851 | |
| Operating Cash Flow Coverage Ratio | 0.305 | 0.324 | 0.382 | 0.274 | 0.210 | |
| Capital Expenditure Coverage Ratio | 7.922 | 7.371 | 7.510 | 6.684 | 6.231 | |
| Dividend Paid And Capex Coverage Ratio | 3.401 | 3.486 | 3.908 | 3.231 | 2.882 | |
| Dividend Payout Ratio | 0.270 | 0.456 | 0.281 | 0.206 | 0.250 | |
| Enterprise Value Multiple | 8.356 | 8.896 | 10.327 | 12.396 | 10.719 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 9.4% | ▼-1.1% | ▼-2.4% |
| Ebit Margin | 3.3% | ▼-0.7% | ▼-1.0% |
| Ebitda Margin | 4.2% | ▼-0.4% | ▼-1.0% |
| Operating Profit Margin | 3.3% | ▼-0.5% | ▼-0.8% |
| Pretax Profit Margin | 2.8% | ▲0.6% | ▼-0.5% |
| Continuous Operations Profit Margin | 2.3% | ▲0.7% | ▼-0.4% |
| Net Profit Margin | 2.2% | ▲0.8% | ▼-0.4% |
| Bottom Line Profit Margin | 2.2% | ▲0.8% | ▼-0.4% |
| Current Ratio | 0.849 | ▲0.006 | ▲0.045 |
| Quick Ratio | 0.718 | ▼-0.009 | ▲0.027 |
| Solvency Ratio | 0.074 | ▲0.029 | ▲0.006 |
| Cash Ratio | 0.136 | ▲0.006 | ▼-0.001 |
| Price To Earnings Ratio | 12.342 | ▼-10.200 | ▼-3.993 |
| Price To Earnings Growth Ratio | 0.150 | ▲0.895 | ▲0.458 |
| Forward Price To Earnings Growth Ratio | 0.150 | ▲0.895 | ▲0.458 |
| Price To Earnings Diluted Ratio | 12.415 | ▼-10.369 | ▼-4.080 |
| Price To Earnings Diluted Growth Ratio | 0.150 | ▲0.901 | ▲0.460 |
| Price To Book Ratio | 1.755 | ▼-0.132 | ▼-0.150 |
| Price To Sales Ratio | 0.266 | ▼-0.047 | ▼-0.145 |
| Price To Free Cash Flow Ratio | 8.725 | ▲0.084 | ▼-1.874 |
| Price To Operating Cash Flow Ratio | 7.624 | ▲0.155 | ▼-1.455 |
| Debt To Assets Ratio | 0.199 | ▼-0.006 | ▼-0.010 |
| Debt To Equity Ratio | 0.754 | ▼-0.025 | ▲0.028 |
| Debt To Capital Ratio | 0.430 | ▼-0.008 | ▲0.009 |
| Long Term Debt To Capital Ratio | 0.425 | ▲0.012 | ▲0.026 |
| Financial Leverage Ratio | 3.786 | ▼-0.013 | ▲0.309 |
| Working Capital Turnover Ratio | -31.179 | ▼-7.039 | ▼-8.299 |
| Operating Cash Flow Ratio | 0.170 | ▼-0.008 | ▼-0.023 |
| Operating Cash Flow Sales Ratio | 0.035 | ▼-0.007 | ▼-0.010 |
| Free Cash Flow Operating Cash Flow Ratio | 0.874 | ▲0.009 | ▲0.015 |
| Debt Service Coverage Ratio | 5.201 | ▲2.953 | ▲2.317 |
| Interest Coverage Ratio | 6.610 | ▲0.048 | ▲0.104 |
| Short Term Operating Cash Flow Coverage Ratio | 16.218 | ▲12.754 | ▲10.262 |
| Operating Cash Flow Coverage Ratio | 0.305 | ▼-0.019 | ▲0.006 |
| Capital Expenditure Coverage Ratio | 7.922 | ▲0.551 | ▲0.778 |
| Dividend Paid And Capex Coverage Ratio | 3.401 | ▼-0.085 | ▲0.019 |
| Dividend Payout Ratio | 0.270 | ▼-0.186 | ▼-0.022 |
| Enterprise Value Multiple | 8.356 | ▼-0.540 | ▼-1.783 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $73.20B | $77.40B | $88.90B | $103.73B | $77.61B | |
| Enterprise value | $96.98B | $101.82B | $112.01B | $129.36B | $106.79B | |
| EV / Sales | 0.35x | 0.41x | 0.57x | 0.72x | 0.61x | |
| EV / Op. cash flow | 10.10x | 9.83x | 9.48x | 14.95x | 14.85x | |
| EV / Free cash flow | 11.56x | 11.37x | 10.94x | 17.57x | 17.69x | |
| EV / EBITDA | 8.36x | 8.90x | 10.33x | 12.40x | 10.72x | |
| Net debt / EBITDA | 2.05x | 2.13x | 2.13x | 2.46x | 2.93x | |
| Current ratio | 0.85x | 0.84x | 0.77x | 0.73x | 0.83x | |
| Income quality | 1.53x | 2.74x | 2.20x | 1.28x | 1.33x | |
| Graham number | $281 | $201 | $247 | $263 | $223 | |
| Graham net-net | -$313 | -$303 | -$275 | -$246 | -$263 | |
| Tax burden | 78.5% | 65.2% | 93.7% | 79.8% | 79.1% | |
| Interest burden | 84.6% | 54.4% | 61.0% | 97.9% | 83.2% | |
| Working capital | -$8.53B | -$9.11B | -$11.37B | -$11.10B | -$7.44B | |
| Invested capital | $68.61B | $68.33B | $67.45B | $71.35B | $76.95B | |
| Return on assets | 3.8% | 2.2% | 3.4% | 4.7% | 3.5% | |
| Operating ROA | 5.8% | 6.1% | 5.8% | 5.7% | 5.1% | |
| Return on tangible assets | 7.1% | 4.3% | 6.9% | 10.7% | 7.4% | |
| Return on equity | 14.3% | 8.4% | 11.2% | 14.9% | 11.4% | |
| Return on invested capital | 7.4% | 6.7% | 7.8% | 6.5% | 5.6% | |
| Return on capital employed | 9.0% | 9.6% | 8.2% | 8.2% | 7.1% | |
| Earnings yield | 8.1% | 4.4% | 5.8% | 6.5% | 6.9% | |
| Free cash flow yield | 11.5% | 11.6% | 11.5% | 7.1% | 7.8% | |
| Capex / Op. cash flow | 12.6% | 13.6% | 13.3% | 15.0% | 16.0% | |
| Capex / Depreciation | 43.7% | 50.7% | 51.8% | 44.1% | 39.5% | |
| Capex / Sales | 0.4% | 0.6% | 0.8% | 0.7% | 0.7% | |
| SG&A / Sales | 5.1% | 5.9% | 7.3% | 7.2% | 7.3% | |
| R&D / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Stock comp / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Intangibles / Total assets | 46.5% | 49.1% | 51.0% | 56.4% | 53.4% | |
| Days sales outstanding | 38d | 36d | 33d | 34d | 31d | |
| Days payables outstanding | 16d | 62d | 61d | 58d | 53d | |
| Operating cycle | 49d | 47d | 45d | 45d | 40d | |
| Cash conversion cycle | 33d | -16d | -16d | -12d | -13d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▼-5.4%EV / Sales ▼-14.4%EV / EBITDA ▼-6.1%EV / Op. cash flow ▲+0.276Earnings yield ▲+0.037Graham number ▲+80.270
Profitability
Return on equity ▲+0.059Return on assets ▲+0.016Return on invested capital ▲+0.007Return on capital employed ▼-0.006Operating ROA ▼-0.003Income quality ▼-1.216Tax burden ▲+0.133
Efficiency
Days sales outstanding ▲+2.645Days payables outstanding ▼-46.691Operating cycle ▲+2.359Cash conversion cycle ▲+49.050Capex / Sales ▼-0.001R&D / Sales n/a
Balance-sheet strength
Current ratio ▲+0.006Net debt / EBITDA ▼-0.084Working capital ▲+581000000.000Invested capital ▲+275000000.000Intangibles / Total assets ▼-0.026
Change over 5 years
Valuation
Market cap ▼-5.7%EV / Sales ▼-42.5%EV / EBITDA ▼-22.0%EV / Op. cash flow ▼-4.749Earnings yield ▲+0.012Graham number ▲+57.912
Profitability
Return on equity ▲+0.029Return on assets ▲+0.003Return on invested capital ▲+0.018Return on capital employed ▲+0.019Operating ROA ▲+0.007Income quality ▲+0.200Tax burden ▼-0.006
Efficiency
Days sales outstanding ▲+7.544Days payables outstanding ▼-37.424Operating cycle ▲+9.312Cash conversion cycle ▲+46.736Capex / Sales ▼-0.002R&D / Sales n/a
Balance-sheet strength
Current ratio ▲+0.019Net debt / EBITDA ▼-0.880Working capital ▼-1090000000.000Invested capital ▼-8341000000.000Intangibles / Total assets ▼-0.069
Employee count
Peer market caps
Recent news
- 2026-10-01 Cigna: Deeply Undervalued With Expected Double-Digit EPS Growth Ahead Cigna is rated a ''Strong Buy'' for its compelling value, robust earnings growth, and capital returns at a forward P/E of 8.9x. CI posted strong Q2 2026 results, raised full-year EPS guidance, and targets 10–14% annual EPS growth through 2030, driven by AI and specialty pharmacy. CI''s asset-light model, expanding specialty pharma presence, and aggressive share buybacks support high-teens total return potential annually.
- 2026-10-01 The Cigna Group (CI) Analyst/Investor Day Transcript The Cigna Group (CI) Analyst/Investor Day Transcript
- 2026-09-30 Cigna Reaffirms 2026 Outlook, Targets Complex Care and AI-Driven Growth Cigna Group NYSE: CI reaffirmed its 2026 outlook and outlined a long-term strategy centered on complex care, technology-enabled personalization and disciplined capital deployment at its 2026 Investor Day.
- 2026-09-30 Cigna Group (CI) Reaffirms FY26 Guidance Amid Investor Day Insights The Cigna Group (CI) shares are experiencing a significant decline following the company''s reaffirmation of its FY26 guidance during its Investor Day. Investors
- 2026-09-30 Cigna to invest $3 billion in multi-year initiative to improve workflow Cigna said on Wednesday it will invest $3 billion as part of a multi-year program to focus on modernizing processes and streamlining workflows, among others, with AI-enabled insights and tools to drive growth.
- 2026-09-30 The Cigna Group Hosts 2026 Investor Day; Introduces "Lead to One" to Drive Durable Growth Through Complex Care Leadership and Differentiated Capabilities Following deliberate portfolio shaping over the last several years, The Cigna Group is strategically positioned where health care costs are concentrating with multiple avenues for growth Announces "Lead to One" vision, unifying all colleagues around delivering personalization at scale to improve affordability and the patient experience Distinct, industry-leading capabilities in complex care, powered by clinical expertise, data, technology and AI Announces $3B multi-year modernization and productivity initiative to fuel performance Reaffirms 2026 full-year financial guidance and provides long-term financial growth target of 10-14% adjusted EPS CAGR through 2030 BLOOMFIELD, Conn., Sept. 30, 2026 /PRNewswire/ -- Today, at its Investor Day, The Cigna Group (NYSE: CI) will outline its strategy to improve affordability and personalization across the health care continuum.
- 2026-09-30 Cigna Group (NYSE:CI) Stock Rated “Moderate Buy” by Sell-Side Analysts Cigna Group (NYSE: CI - Get Free Report) has received a consensus rating of "Moderate Buy" from the twenty-three ratings firms that are currently covering the company, Marketbeat.com reports. Eight investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. The average 1 year price target
- 2026-09-29 Cigna Stock in Focus as Investor Day Spotlights Specialty Drugs Cigna Group investors will be looking for more detail on the growth of its specialty pharmacy business under new CEO Brian Evanko.
- 2026-09-28 Why Cigna (CI) is a Top Value Stock for the Long-Term Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
- 2026-09-21 Defying Headwinds, the U.S. Economy Continues to Flex Its Resilience We believe that there is nothing more fundamental and reflective of economic health than the employment situation, and the latest data reflects an economy showing persistent growth. After July''s disappointing payroll print, the August employment report rebounded strongly.